Aditxt Inc (ADTX)
$1.08
Performance
- $1.02$1.10$1.08
6.02%
Downside
Day's Volatility :7.73%
Upside
1.82%
- $1.07$520.00$1.08
0.93%
Downside
52 Weeks Volatility :99.79%
Upside
99.79%
Returns
| Period | Aditxt Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -98.8% | 0.0% |
6 Months | -98.82% | 0.0% |
1 Year | -99.72% | 0.0% |
3 Years | -100.0% | -21.9% |
Highlights
Market Capitalization | 156.3K |
Book Value | $131.74 |
Earnings Per Share (EPS) | -1375.2 |
Wall Street Target Price | 61.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -13497.11% |
Return On Assets TTM | -117.61% |
Return On Equity TTM | -3493.63% |
Revenue TTM | 329.7K |
Revenue Per Share TTM | 12.11 |
Quarterly Revenue Growth YOY | -80.0% |
Gross Profit TTM | 166.9K |
EBITDA | -33.1M |
Diluted Eps TTM | -1375.2 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 5548.15%
Technicals Summary
Sell
Neutral
Buy
Aditxt Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Aditxt Inc | -93.8% | -98.82% | -99.72% | -100.0% | -100.0% |
 Regeneron Pharmaceuticals, Inc. | -12.1% | 11.85% | 20.45% | 85.46% | 234.24% |
 Novo Nordisk A/s | -10.58% | -5.22% | 16.68% | 128.23% | 348.1% |
 Alnylam Pharmaceuticals, Inc. | 9.51% | 106.82% | 81.08% | 47.4% | 267.06% |
 Vertex Pharmaceuticals Incorporated | 1.24% | 23.95% | 30.46% | 169.5% | 174.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Aditxt Inc | NA | NA | NA | 0.0 | -34.94 | -1.18 | NA | 131.74 |
Regeneron Pharmaceuticals, Inc. | 26.93 | 26.93 | 1.38 | 44.91 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 39.94 | 39.94 | 1.84 | 3.37 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Aditxt Inc | Sell | $156.3K | -100.0% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $112.1B | 234.24% | 26.93 | 32.04% |
Novo Nordisk A/s | Buy | $522.1B | 348.1% | 39.94 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $36.9B | 267.06% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $125.0B | 174.17% | 32.84 | -4.74% |
Insights on Aditxt Inc
Decreasing Revenue
Revenue is down for the last 5 quarters, 220.97K → 44.27K (in $), with an average decrease of 31.2% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -14.72M → -7.54M (in $), with an average increase of 95.1% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 81.1% return, outperforming this stock by 180.8%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.1% return, outperforming this stock by 144.1%
Institutional Holdings
Geode Capital Management, LLC
0.31%Tower Research Capital LLC
0.12%Group One Trading, LP
0.02%IFP Advisors, LLC
0.01%
Company Information
a biotech company with a mission to accelerate humanity’s transition to the "age of immunity", we are the business busily decoding the human immune system.
Organization | Aditxt Inc |
Employees | 47 |
CEO | Mr. Amro A. Albanna |
Industry | Health Technology |
